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Structured Summary 29 
Objectives 30 
To test the in vitro antimicrobial efficacy of a non-toxic emulsion of free fatty acids against clinically 31 
relevant canine and feline periodontopathogens for the prevention of periodontitis and gingivitis in 32 
cats and dogs.    33 
Methods 34 
Antimicrobial kill kinetics were established utilising an alamarBlue® viability assay against ten strains 35 
of canine and feline periodontopathogens, in the biofilm mode of growth, at a concentration of 0.125% 36 
v/v medium chain triglyceride (ML:8) emulsion.  The results were compared with 0.12% v/v 37 
chlorhexidine digluconate and a commercially available xylitol-containing dental formulation (Virbac 38 
Vet Aquadent®).  Mammalian cellular cytotoxicity was also investigated for both the ML:8 emulsion 39 
and chlorhexidine digluconate (0.25 to 0.0625% v/v) using in vitro tissue culture techniques. 40 
Results  41 
No statistically significant difference was observed in the antimicrobial activity of 0.125% v/v ML:8 42 
emulsion and 0.12% v/v chlorhexidine digluconate against all ten periodontopathogens tested; a high 43 
percentage kill rate (> 70%) was achieved within 5 minutes of exposure and at subsequent time points 44 
investigated.  A statistically significant improvement in antibiofilm activity was seen with 0.125% v/v 45 
ML:8 emulsion when compared with a currently available xylitol containing drinking water additive 46 
(Virbac Vet Aquadent®).  The ML:8 emulsion possessed a significantly lower (P<0.001) toxicity 47 
profile when compared to 0.12% v/v chlorhexidine digluconate in cytotoxicity assays. 48 
Clinical Significance 49 
The ML:8 emulsion  exhibited significant potential as a putative effective antimicrobial alternative to 50 
chlorhexidine- and xylitol- based products for the prevention of periodontal disease, which, when 51 
compared to chlorhexidine at equivalent concentration, exhibited significantly reduced cytotoxic 52 
characteristics. 53 
 54 
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 56 
Introduction  57 
Periodontitis is the most common described progressive inflammatory disease in companion animal 58 
practice, affecting more than 80-85% of dogs and cats above three years of age (Watson 2006).  59 
Within the oral cavity, the condition refers to inflammation of the tooth support structures leading to 60 
damage and loss of the periodontal membrane, alveolar bone and adjacent soft tissues; the resulting 61 
damage may potentially result in tooth loss.  The severity and prognosis of dental disease is dependent 62 
on multiple factors including species, age, breed, genetics, nutritional status, the presence of irritants, 63 
chewing activity, co-morbidities, dental crowding, occlusion and oral microbial profile (Harvey and 64 
Emily 1993).  The prospect for systemic and chronic diseases to develop subsequent to periodontal 65 
disease is high due to the dense vascular network of the gum tissue (DeBowes et al. 1996).  66 
 67 
The tooth and its supporting structures provide an optimum environment for the growth and 68 
replication of transient microorganisms within the mouth (Wiggs and Lobprise 1997).  Food particles 69 
collect between the teeth to provide a nutrient source for the development of a bacterial biofilm 70 
community (plaque) at the tooth’s surface.  Bacteria, growing as biofilms,  are notoriously difficult to 71 
eradicate, often requiring bactericidal concentrations of 10-1000 times that of free-floating, planktonic 72 
bacteria in suspension. Exposure to sub-optimal or sub-therapeutic antimicrobial concentrations in the 73 
biofilm thereby increases the potential for  antimicrobial resistance development (Stewart and 74 
Costerton 2001).  Within days minerals in the saliva, such as calcium, combine with plaque to form 75 
calculus material (tartar) and an immune response is initiated by the host resulting in the inflammatory 76 
signs of gingivitis and periodontitis, indirect periodontal destruction, pain, halitosis and loss of 77 
appetite (Wiggs and Lobprise 1997). 78 
 79 
The microbial ecology of the oral cavity of cats and dogs is vastly diverse with aerobic bacteria 80 
predominating in the early phase of gingivitis, followed by a predominantly anaerobic and Gram-81 
negative bacterial profile when periodontitis becomes established (Hennet and Harvey 1991) (Harvey 82 
et al. 1995).  The process of bacterial biofilm formation begins on the tooth surface immediately after 83 
successful scaling.  Initially, Gram-positive cocci, including Streptococci (Leonhardt et al. 1992) 84 
(Radice et al. 2006) become attached to the surface.  Further growth and maturation of this aerobic or 85 
facultative flora leads to depletion of locally available oxygen and anaerobes such as Porphyromonas 86 
gingivalis and Fusobacterium nucleatum become more predominant (Cleland 2001).  As gingival 87 
inflammation develops in response to the presence of bacteria, metabolic and inflammatory products 88 
such as endotoxins become constitute major components of the gingival fluid,  contributing to local 89 
oral and systemic tissue destruction and dental bone loss (Holmstrom and others 2004).  Invasive 90 
pathogens capable of active spread through the systemic blood supply may colonise other highly 91 
vascularised tissues including the kidneys, liver and heart.  These micro-abscesses reduce overall long-92 
term health for the animal, increasing risk factors associated with heart disease, hypertension and 93 
kidney disease (Glickman et al. 2011). 94 
 95 
For both cats and dogs, treatment of established infection centres on the use of antibiotics and anti-96 
inflammatory agents, along with dental scaling and polishing (physical removal of calculus) 97 
performed by a veterinary practitioner.  Scaling and removal of subgingival plaque is particularly 98 
problematic, often requiring administration of a general anaesthetic with the procedure repeated 99 
regularly throughout the animal’s lifetime (Harvey 2005).  Preventative therapy is typically centred on 100 
mechanical removal of adhered bacteria with a routine of regular toothbrushing aided by veterinary 101 
toothpastes containing antimicrobials ranging from chlorhexidine digluconate and cetylpyridium 102 
chloride to enzyme-based formulations.  However, in addition to pet compliance issues, the effective 103 
removal of plaque requires the pet owner to be manually dexterous and patient (Iacono et al. 1998). In 104 
real-life practice, these factors often limit successful compliance. 105 
 106 
This study describes the formulation of an antimicrobial emulsion, intended for buccal application in 107 
companion animals, comprising of a medium chain triglyceride (ML:8) oil phase dispersed in water 108 
that displays in vitro efficacy at a low concentration (0.125% v/v) against resistant biofilm forms of 109 
ten periodontopathogens clinically implicated in canine and feline dental disease (Elliot et al. 2005) 110 
(Kolenbrander et al. 2002).  This antimicrobial emulsion has the potential to be utilised as a drinking 111 
water additive to increase ease of use for the pet owner and subsequent aid compliance, with the 112 
overall aims of reducing long-term oral bacterial bioburden and the incidence of periodontal disease in 113 
both cats and dogs.   114 
 115 
Materials and Methods  116 
Formulation of ML:8 Emulsion
 
117 
The antimicrobial composition of ML:8 consists of an oil in water emulsion.  A mixture of free fatty 118 
acids solubilised in water is promoted by the addition of membrane lipids, in this case lecithin.  Lower 119 
melting point fatty acids such as caprylic and oleic acid were utilised to a final concentration of 120 
6.375% w/w.  The ratio of free fatty acids to membrane lipid was 1.275:1.  The final formulation was 121 
freshly diluted 1 in 51 (0.125% v/v free fatty acids) in sterile water before analysis.  122 
 123 
Comparator Substances 124 
Chlorhexidine digluconate was obtained from Sigma-Aldrich (Dorset, UK). A commercially available 125 
drinking water additive (Virbac Vet Aquadent®) containing xylitol 0.5% concentration (with 126 
chlorhexidine <0.01%) was obtained from Virbac (Bury St Edmonds, UK). 127 
 128 
Microbial Isolates Investigated 129 
Haemophilus actinomycetemcomitans (NCTC 10979), Streptococcus sanguinis (NCTC 10904) were 130 
obtained from HPA Culture Collections (Salisbury, UK).  Porphyromonas cangingivalis (VPB 4874), 131 
Porphyromonas salivosa (VPB 3313), Porphyromonas gingivalis (VPB 5089), Fusobacterium 132 
nucleatum (VPB 4888), Eikenella corrodens (VPB 3935), Bacteroides fragilis (VPB 3371), Prevotella 133 
intermedia (VPB 3321) and Tanerrella forsythesis (VPB 4947) were obtained from Dr Denise 134 
Wigney, Faculty of Veterinary Science, University of Sydney, Australia.  All isolates of 135 
microorganisms were stored at -80°C in 10% glycerol. 136 
 137 
Rate of Reduction in Viability of Periodontal Biofilms using an alamarBlue® Assay 138 
Microorganisms under investigation were grown over 48-72 hours at 37°C in Tryptone Soya broth in a 139 
Biomat Class II Microbiological anaerobic Safety Cabinet (Don Whitely Scientific Ltd., Shipley, UK).  140 
Upon visual confirmation of growth, the inoculum and adjusted to an optical density of 0.3 at 550nm 141 
in QSRS solution, which was equivalent to 1x108 colony forming units per milliliter (CFU/mL).  This 142 
suspension was further diluted in Tryptone Soya broth (TSB) (1 in 50) and dispensed aseptically in 143 
100µL aliquots to each well of the microtitre plate.  The inoculated plates were placed in Anaerogen 144 
sachets (Oxoid, Hampshire, UK) and the air tight sachets containing the inoculated plates were 145 
removed from the cabinet and biofilm were formed on the surface of the well under shear stress 146 
provided by a Gallenkamp gyrorotary incubator at 37ºC.  After an inoculation period of 48 hours, the 147 
Anaerogen sachets containing the biofilm growth plates were transferred to the anaerobic cabinet, 148 
cultures were decanted and the plates irrigated twice with 200µL of sterile autoclaved 0.9% w/v 149 
sodium chloride (NaCl) in each well.  Washed plates were tapped gently upside down on a sterile 150 
paper towel to remove residual wash.  The prepared biofilm was treated for evaluation of viability 151 
using alamarBlue® in a method similar to that used by Pettit et al. (2005).  The viability of established 152 
biofilms was assessed by re-charging wells from above immediately after washing and without drying, 153 
with 0.1mL fresh TSB broth containing 20% v/v alamarBlue® (AbD Serotec, Oxford, UK), incubating 154 
the plate at 37°C for one hour followed by spectrophotometric measurement of absorbance at a 155 
wavelength of 570nm.  AlamarBlue® is resazurin, a redox indicator which is reduced by metabolic 156 
activity of viable microbial cells to pink fluorescent resorfurin.  The reduction of viability (killing) of 157 
established biofilm with the test formulations was evaluated by loading wells containing washed 158 
biofilm from above immediately after washing with 0.1mL of 0.125% v/v ML:8 emulsion, 0.12% v/v 159 
chlorhexidine digluconate or xylitol followed by incubation at 37ºC.  Time points selected for analysis 160 
of ML:8 emulsion/chlorhexidine digluconate/xylitol activity on established biofilms were 0, 5, 10, 20, 161 
30, 40, 50 and 60 minutes, followed by 2, 4 and 24 hours.  Each control well had 8 replicates at each 162 
time point.  Blank determinations (100% viability: positive control) were conducted using sterile 163 
distilled water.  Immediately following incubation, the exposed biofilms were washed twice by 164 
irrigation with sterile 0.9% w/v NaCl and recharged with fresh TSB containing 20% v/v alamarBlue® 165 
(sterilized by passage twice through a syringe fitted with a  0.22µm membrane filter) and 3% w/v 166 
Tween 80 (polysorbate), incubated at 37°C for 1 hour and the development of UV absorbance was then 167 
measured spectrophotometrically at 570nm.  A positive control (100% microbicidal effect) was also 168 
included in the assay using 2% chlorhexidine digluconate.  Reduction in viability of biofilm following 169 
exposure to the test formulations was expressed as a percentage based on the percentage reduction 170 
between untreated (blank) wells and treated wells using the following equation: 171 
 172 
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 174 
Cell Survival Analysis (cytotoxicity assays) 
 
175 
Two individual mammalian cell lines were selected for cytotoxicity analysis following exposure to the 176 
test formulations.  These were Het-1A (ATCC CRL-2692) human oesophageal cells and NCTC Clone 177 
929 (ATCC CCL 1) murine fibroblast subcutaneous connective tissue cells; areolar and adipose 178 
International Standard cell lines.  Both cell lines were obtained from LGC Standards (London, UK).  179 
NCTC Clone 929 (ATCC CCL 1) cell line was cultured in Minimum Essential Medium (MEM) 180 
containing phenol red with Earle’s Salts, L-Glutamine, supplemented with 10% Horse 181 
Serum,100iu/mL penicillin and 100µg/mL streptomycin supplied by Invitrogen (Paisley, UK).  The 182 
Het-1A (ATCC CRL-2692) cell line was cultured in Bronchial Epithelial cell Basal Medium (BEBM) 183 
supplemented by Bronchial Epithelial Cell Growth Medium (BEGM) SingleQuot Kit and Growth 184 
Factors (Lonza, Basle, Switzerland).  Cells were grown at 37ºC and 5% CO2 and subcultured at 80 – 185 
90 % confluency.  Subculturing consisted of removal of spent medium, rinsing of the adherent cell 186 
surface with sterile autoclaved phosphate buffered saline (PBS) before treatment with a 0.05% 187 
Trypsin/0.53mM EDTA·4Na solution (Invitrogen, Paisley, UK) for cell monolayer detachment.  For 188 
the Het-1A (ATCC CRL-2692) cell line Trypsin/EDTA required inclusion of 0.5% 189 
polyvinylpyrrolidone (Sigma-Aldrich, Dorset, UK) and preparation flasks were required to be 190 
precoated with 0.01mg/mL fibronectin, 0.03mg/mL bovine collagen type I and 0.01mg/mL bovine 191 
serum albumin (all supplied by Invitrogen, Paisley, UK) to facilitate attachment. 192 
 193 
Cell viability was assessed by means of a quantitative alamarBlue® assay, using a modification of the 194 
method of O’Brien et al. (2000).  Cells were cultured (until at least third passage) and inoculated into 195 
96-well tissue culture treated microtitre plates at a concentration of 1 x 104 cells/well and incubated at 196 
37°C and 5% CO2 for 24 ± 1hour, until approximately 90% confluency as described above.  After this 197 
time, the medium was removed and replaced with required fresh growth medium, containing doubling 198 
dilutions of ML:8 emulsion at final concentrations of 0.25-0.0625% v/v with eight replicates at each 199 
concentration.  Chlorhexidine digluconate was tested over the same concentration range and acted as a 200 
comparative control.  Time points selected for analysis of ML:8 emulsion/chlorhexidine digluconate 201 
activity on established cell lines were 5, 30 and 60 minutes.  Absorption was measured at 570nm in a 202 
Tecan Sunrise® plate reader after a development time of 10 hours for NCTC Clone 929 (ATCC CCL 203 
1) cell line and 4 hours for Het-1A (ATCC CRL-2692) cell line.  A positive control (100% reduction 204 
in viability) was also included in the assay using 90% ethanol (Sigma-Aldrich, Dorset, UK); the 205 
negative control consisted of untreated cell line wells  percentage cell viability was calculated relative 206 
to untreated control wells after subtraction of the blank value corresponding to untreated cells in the 207 
absence of alamarBlue® reagent. 208 
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 211 
Statistical Analysis 212 
Statistical analyses were performed using GraphPad InStat 3.  Standard deviations were obtained at 213 
each concentration/timepoint of antimicrobials tested based on eight replicates for both quantitative 214 
biofilm and cell cytotoxicity viability assays and mean values obtained.  Further statistical analysis 215 
was employed using a one way Analysis of Variance (ANOVA), with a Tukey-Kramer multiple 216 
comparisons test used to identify individual differences between the antibiofilm activity of 0.125% v/v 217 
ML:8 emulsion and 0.12% v/v chlorhexidine digluconate, and also the antibiofilm activity of 0.125% 218 
v/v ML:8 emulsion and 2.4% v/v Virbac Vet Aquadent® (as directed by the manufacturer), at relative 219 
timepoints.  ANOVA with a Tukey-Kramer multiple comparisons test was also utilised for statistical 220 
analysis of cytotoxicity data of ML:8 emulsion and chlorhexidine digluconate at the same 221 
concentrations (0.25-0.06125% v/v) and relative timepoints.  ANOVA assumes that the data is 222 
sampled from populations that follow Gaussian distributions. Data was shown to be normally 223 
distributed using the Kolmogorov and Smirnov method.  In all cases a probability of P ≤ 0.05 denoted 224 
significance. 225 
 226 
Results 227 
The 0.125% v/v ML:8 emulsion displayed significant activity against biofilm forms of the 10 228 
periodontopathogens investigated within 5 to 10 minutes exposure.  Antibiofilm efficacy was 229 
significantly greater than the 2.4% v/v Virbac Vet Aquadent® (xylitol containing formulation) and 230 
statistically similar to 0.12% v/v chlorhexidine digluconate.  Antibiofilm activity for 0.125% v/v ML:8 231 
emulsion, 0.12% v/v chlorhexidine digluconate and xylitol containing formulation are displayed in 232 
Figures 1-10.  ML:8 emulsion was significantly less cytotoxic than chlorhexidine digluconate at 233 
similar concentrations (P < 0.001 for all assays). Cytotoxicity of ML:8 emulsion and chlorhexidine 234 
digluconate at the same concentrations (0.25-0.06125% v/v) against CCL 1 (NCTC Clone 929) murine 235 
fibroblast subcutaneous connective tissue monolayer cells and human oesophageal tissue monolayer 236 
cells (ATCC CRL-2692) are shown in Figures 11 and 12, respectively. 237 
 238 
Discussion  239 
The results of the current study demonstrate that ML:8 emulsion displayed a high degree of potency 240 
against 48 hour biofilm forms of the 10 periodontopathogens investigated.  High percentage kill rates 241 
(> 70%) were achieved against the majority of test organisms within 5 minutes of exposure, and at all 242 
subsequent time points.  The selection of biofilm forms of bacteria was purposeful in order to test the 243 
ability of the formulation to eradicate this more resistant bacterial phenotype present within the oral 244 
cavity (Hojo et al. 2009).  The majority of previously reported dental-related studies have centred on 245 
human plaque and less resistant liquid planktonic forms of bacteria (Stanley et al. 1989) (McBain et 246 
al. 2004), and whilst contributing valuable information, their clinical relevance may be limited  in 247 
comparison to biofilm-based data.  The bacteria selected for assessment in the current study were 248 
derived from an extensive literature search for relevant canine and feline periodontopathogens, and as 249 
such, have direct relevance to the clinical microbiota encountered in canine/feline periodontal disease 250 
(Syed and Svanberg 1981)(Svanberg et al. 1982)(Hennet and Harvey 1991)(Leonhardt et al. 251 
1992)(Okuda and Harvey 1992)(Harvey et al. 1995)(Harvey 1998)(Harvey 2005).   252 
 253 
The antimicrobial activity of free fatty acids has been widely reported previously in the literature 254 
(Kabara et al. 1972).  Research conducted by Sun et al. (2002) concluded that caprylic (C8), capric 255 
(C10) and lauric acid (C12) displayed antimicrobial activity with lauric and caprylic acid shown to be 256 
most efficacious against Gram-positive and Gram-negative bacteria, respectively.  The ML:8 emulsion 257 
formulation described here displayed rapid antimicrobial efficacy, showing high potential to be an 258 
effective drinking water additive for periodontal disease prevention at low concentrations (0.125% 259 
v/v), despite the limited exposure times that can be achieved within the oral cavity.  To test this 260 
hypothesis further, we compared the anti-biofilm activity of the ML:8 emulsion with the gold standard 261 
in human/veterinary dental hygiene (0.12% chlorhexidine digluconate) and another commercially 262 
available veterinary dental formulation containing 0.5% xylitol (prediluted). With the exception of the 263 
0 minute timepoints for Porphyromonas gingivalis (VPB 5089), Eikenella corrodens (VPB 3935) and 264 
Tanerrella forsythensis (VPB 4947), there was no significant difference in the antibiofilm activity of 265 
0.125% v/v ML:8 emulsion and 0.12% v/v chlorhexidine digluconate (P>0.05).  However, although 266 
chlorhexidine has been a mainstay in the control and treatment of dental pathogens in human health 267 
(Roberts et al. 2002), similar effective concentrations cannot be employed in canine drinking water 268 
formulations as the ingestion/swallowing of solutions containing 0.12%v/v chlorhexidine on a daily 269 
basis is likely to be associated with significant cytotoxicity, as demonstrated by the results generated 270 
in this study (see later).   At concentrations significantly below the traditional 0.12%v/v threshold 271 
employed in human products, the range of chlorhexidine-based drinking water additives available on 272 
the veterinary market have debatable in vitro and in vivo efficacy (Roudebush et al. 2005).   273 
 274 
Virbac Vet Aquadent® contains xylitol and <0.05% chlorhexidine digluconate (the chlorhexidine 275 
component is not included as an active ingredient). Our results show Aquadent® to have limited 276 
efficacy against biofilm forms of periodontal bacteria tested up to 24 hours under the conditions of this 277 
assay.  At the 24 hour timepoint, the reduction in viable biofilm reached a maximum of 53% against 278 
Eikenella corrodens (VPB 3935).  The majority of bacteria/timepoints studied showed a mean 279 
reduction of biofilm of less than 10%.   Overall, the 0.125% v/v ML:8 emulsion showed a statistically 280 
significant increase in biofilm reduction when compared with Aquadent® in 93.6% of the comparative 281 
time points/bacteria tested (103 out of 110 sample points; P < 0.001).  Although issues have been 282 
raised in relation to the potential toxic effects of xylitol ingestion in dogs (Murphy et al. 2012), the 283 
dose levels employed in Aquadent® have not been associated with any reported toxic effects in the 284 
published literature. 285 
 286 
Figures 11 and 12 show that at therapeutic concentrations (0.12% v/v) chlorhexidine digluconate 287 
demonstrated toxicity against mammalian cell lines; therefore, its long-term use or suitability as a 288 
drinking water additive may be limited by potential gastrointestinal and oral mucosal damage.  At the 289 
same concentrations and correlating to the same exposure times and cell lines, the toxicity 290 
demonstrated by ML:8 emulsion was significantly lower (P<0.001) than for chlorhexidine 291 
digluconate.  After up to 60 minutes exposure to varying concentrations of ML:8 emulsion (0.25 to 292 
0.0625%v/v), the relative percentage kill of CCL 1 (NCTC Clone 929) murine fibroblast cells was 293 
absent (0%).  The results obtained for chlorhexidine digluconate against both human oesophageal 294 
tissue (ATCC CRL-2692) and the International cytotoxicity standard CCL 1 (NCTC Clone 929) 295 
murine fibroblast cells showed a statistically significant increase (P<0.001 ) in the cytotoxic activity of 296 
chlorhexidine digluconate relative to ML:8 at all time points studied.  Quantitative evaluations such as 297 
the alamarBlue® assay determine that a reduction of cell viability by more than 30% is indicative of 298 
cytotoxicity (International Standard ISO10993-5).  Selection of the International cytotoxicity standard 299 
CCL 1 (NCTC Clone 929) murine fibroblast cell line allowed this novel formulation to be assessed for 300 
cytotoxicity in general, whilst selection of a mammalian oesophageal cell line also allowed the toxicity 301 
of ML:8 to be compared to a clinically relevant cell line.  302 
 303 
Conclusions 304 
The formulation and 1 in 51 dilution of this novel 6.375% v/v ML:8 emulsion to drinking water  305 
allows the active free fatty acids to be present at an antimicrobially active and non-cytotoxic 0.125 % 306 
v/v final concentration.  Such a product can increase compliance and ease of use allowing daily 307 
administration to help prevent periodontal disease, with superior in vitro results compared with a 308 
currently available xylitol-based drinking water additive.  The findings of this study validate the use of 309 
the ML:8 emulsion as part of an ever increasing evidence-based approach to biofilm control in 310 
veterinary dental applications (Hamp and others 1973).  Although in vivo clinical trials are now 311 
indicated to corroborate these findings, our initial laboratory results show large scope and promise for 312 
continuing research in this area.   313 
 314 
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Figure/Legends 400 
 401 
Fig.  1. Mean percentage reduction in 48 hour biofilm of Haemophilus actinomycetemcomitans 402 
(NCTC 10979) over a period of 24 hour exposure to food grade 0.125%v/v ML:8 Emulsion, 403 
0.12%v/v Chorhexidine digluconate and 2.4%v/v Virbac Vet Aquadent® utilising an 404 
alamarBlue® assay.  Results are displayed as the mean of 8 replicates.  Key: ■: 0.12%v/v 405 
Chlorhexidine digluconate, ▲: 0.125%v/v ML:8 Emulsion, ●: 2.4%v/v Virbac Vet Aquadent®,  406 
ns: no significant difference   (P>0.05) *: P<0.05, **: P<0.01, ***: P<0.001, significant difference 407 
between efficacy of 0.125%v/v ML:8 Emulsion and 0.12%v/v Chorhexidine digluconate or 408 
2.4%v/v Virbac Vet Aquadent® at same timepoint.  409 
 410 
 411 
 412 
Fig.  2. Mean percentage reduction in 48 hour biofilm of Streptococcus sanguinis (NCTC 10904) 413 
over a period of 24 hour exposure to food grade 0.125%v/v ML:8 Emulsion, 0.12%v/v 414 
Chorhexidine digluconate and 2.4%v/v Virbac Vet Aquadent® utilising an alamarBlue® assay.  415 
Results are displayed as the mean of 8 replicates.  Key: ■: 0.12%v/v Chlorhexidine digluconate, 416 
▲: 0.125%v/v ML:8 Emulsion, ●: 2.4%v/v Virbac Vet Aquadent®,  ns: no significant difference   417 
(P>0.05) *: P<0.05, **: P<0.01, ***: P<0.001, significant difference between efficacy of 418 
0.125%v/v ML:8 Emulsion and 0.12%v/v Chorhexidine digluconate or 2.4%v/v Virbac Vet 419 
Aquadent® at same timepoint.  420 
 421 
 422 
 423 
 424 
Fig.  3. Mean percentage reduction in 48 hour biofilm of Porphyromonas cangingivalis (VPB 425 
4874) over a period of 24 hour exposure to food grade 0.125%v/v ML:8 Emulsion, 0.12%v/v 426 
Chorhexidine digluconate and 2.4%v/v Virbac Vet Aquadent® utilising an alamarBlue® assay.  427 
Results are displayed as the mean of 8 replicates.  Key: ■: 0.12%v/v Chlorhexidine digluconate, 428 
▲: 0.125%v/v ML:8 Emulsion, ●: 2.4%v/v Virbac Vet Aquadent®,  ns: no significant difference   429 
(P>0.05) *: P<0.05, **: P<0.01, ***: P<0.001, significant difference between efficacy of 430 
0.125%v/v ML:8 Emulsion and 0.12%v/v Chorhexidine digluconate or 2.4%v/v Virbac Vet 431 
Aquadent® at same timepoint.  432 
 433 
 434 
 435 
 436 
 437 
 438 
Fig.  4. Mean percentage reduction in 48 hour biofilm of Porphyromonas salivosa (VPB 3313) 439 
over a period of 24 hour exposure to food grade 0.125%v/v ML:8 Emulsion, 0.12%v/v 440 
Chorhexidine digluconate and 2.4%v/v Virbac Vet Aquadent® utilising an alamarBlue® assay.  441 
Results are displayed as the mean of 8 replicates.  Key: ■: 0.12%v/v Chlorhexidine digluconate, 442 
▲: 0.125%v/v ML:8 Emulsion, ●: 2.4%v/v Virbac Vet Aquadent®,  ns: no significant difference   443 
(P>0.05) *: P<0.05, **: P<0.01, ***: P<0.001, significant difference between efficacy of 444 
0.125%v/v ML:8 Emulsion and 0.12%v/v Chorhexidine digluconate or 2.4%v/v Virbac Vet 445 
Aquadent® at same timepoint.  446 
 447 
 448 
Fig.  5. Mean percentage reduction in 48 hour biofilm of Porphyromonas gingivalis (VPB 5089) 449 
over a period of 24 hour exposure to food grade 0.125%v/v ML:8 Emulsion, 0.12%v/v 450 
Chorhexidine digluconate and 2.4%v/v Virbac Vet Aquadent® utilising an alamarBlue® assay.  451 
Results are displayed as the mean of 8 replicates.  Key: ■: 0.12%v/v Chlorhexidine digluconate, 452 
▲: 0.125%v/v ML:8 Emulsion, ●: 2.4%v/v Virbac Vet Aquadent®,  ns: no significant difference   453 
(P>0.05) *: P<0.05, **: P<0.01, ***: P<0.001, significant difference between efficacy of 454 
0.125%v/v ML:8 Emulsion and 0.12%v/v Chorhexidine digluconate or 2.4%v/v Virbac Vet 455 
Aquadent® at same timepoint.  456 
 457 
 458 
Fig.  6. Mean percentage reduction in 48 hour biofilm of Fusobacterium nucleatum (VPB 4888) 459 
over a period of 24 hour exposure to food grade 0.125%v/v ML:8 Emulsion, 0.12%v/v 460 
Chorhexidine digluconate and 2.4%v/v Virbac Vet Aquadent® utilising an alamarBlue® assay.  461 
Results are displayed as the mean of 8 replicates.  Key: ■: 0.12%v/v Chlorhexidine digluconate, 462 
▲: 0.125%v/v ML:8 Emulsion, ●: 2.4%v/v Virbac Vet Aquadent®,  ns: no significant difference   463 
(P>0.05) *: P<0.05, **: P<0.01, ***: P<0.001, significant difference between efficacy of 464 
0.125%v/v ML:8 Emulsion and 0.12%v/v Chorhexidine digluconate or 2.4%v/v Virbac Vet 465 
Aquadent® at same timepoint.  466 
 467 
Fig.  7. Mean percentage reduction in 48 hour biofilm of Eikenella corrodens (VPB 3935) over a 468 
period of 24 hour exposure to food grade 0.125%v/v ML:8 Emulsion, 0.12%v/v Chorhexidine 469 
digluconate and 2.4%v/v Virbac Vet Aquadent® utilising an alamarBlue® assay.  Results are 470 
displayed as the mean of 8 replicates.  Key: ■: 0.12%v/v Chlorhexidine digluconate, ▲: 471 
0.125%v/v ML:8 Emulsion, ●: 2.4%v/v Virbac Vet Aquadent®,  ns: no significant difference   472 
(P>0.05) *: P<0.05, **: P<0.01, ***: P<0.001, significant difference between efficacy of 473 
0.125%v/v ML:8 Emulsion and 0.12%v/v Chorhexidine digluconate or 2.4%v/v Virbac Vet 474 
Aquadent® at same timepoint.  475 
 476 
 477 
Fig.  8. Mean percentage reduction in 48 hour biofilm of Bacteroides fragilis (VPB 3371) over a 478 
period of 24 hour exposure to food grade 0.125%v/v ML:8 Emulsion, 0.12%v/v Chorhexidine 479 
digluconate and 2.4%v/v Virbac Vet Aquadent® utilising an alamarBlue® assay.  Results are 480 
displayed as the mean of 8 replicates.  Key: ■: 0.12%v/v Chlorhexidine digluconate, ▲: 481 
0.125%v/v ML:8 Emulsion, ●: 2.4%v/v Virbac Vet Aquadent®,  ns: no significant difference   482 
(P>0.05) *: P<0.05, **: P<0.01, ***: P<0.001, significant difference between efficacy of 483 
0.125%v/v ML:8 Emulsion and 0.12%v/v Chorhexidine digluconate or 2.4%v/v Virbac Vet 484 
Aquadent® at same timepoint.  485 
 486 
Fig.  9. Mean percentage reduction in 48 hour biofilm of Prevotella intermedia (VPB 3321) over a 487 
period of 24 hour exposure to food grade 0.125%v/v ML:8 Emulsion, 0.12%v/v Chorhexidine 488 
digluconate and 2.4%v/v Virbac Vet Aquadent® utilising an alamarBlue® assay.  Results are 489 
displayed as the mean of 8 replicates.  Key: ■: 0.12%v/v Chlorhexidine digluconate, ▲: 490 
0.125%v/v ML:8 Emulsion, ●: 2.4%v/v Virbac Vet Aquadent®,  ns: no significant difference   491 
(P>0.05) *: P<0.05, **: P<0.01, ***: P<0.001, significant difference between efficacy of 492 
0.125%v/v ML:8 Emulsion and 0.12%v/v Chorhexidine digluconate or 2.4%v/v Virbac Vet 493 
Aquadent® at same timepoint.  494 
 495 
 496 
Fig.  10. Mean percentage reduction in 48 hour biofilm of Tanerrella forsythesis (VPB 4947) over 497 
a period of 24 hour exposure to food grade 0.125%v/v ML:8 Emulsion, 0.12%v/v Chorhexidine 498 
digluconate and 2.4%v/v Virbac Vet Aquadent® utilising an alamarBlue® assay.  Results are 499 
displayed as the mean of 8 replicates.  Key: ■: 0.12%v/v Chlorhexidine digluconate, ▲: 500 
0.125%v/v ML:8 Emulsion, ●: 2.4%v/v Virbac Vet Aquadent®,  ns: no significant difference   501 
(P>0.05) *: P<0.05, **: P<0.01, ***: P<0.001, significant difference between efficacy of 502 
0.125%v/v ML:8 Emulsion and 0.12%v/v Chorhexidine digluconate or 2.4%v/v Virbac Vet 503 
Aquadent® at same timepoint.  504 
 505 
 506 
 507 
 508 
Fig.  11. The percentage kill of CCL 1 [NCTC clone 929]- murine fibroblasts subcutaneous 509 
connective tissue monolayer cells after 5, 30 and 60 minutes exposure to varying concentrations 510 
of ML:8 emulsion and Chlorhexidine digluconate (CHX).  Results are obtained via the use of an 511 
alamarBlue® assay (10 hour development time).  Key: 512 
 513 
ns: no significant difference (P>0.05), *: P<0.05, **: P<0.01, ***: P<0.001, significant difference 514 
between cytotoxicity of ML:8 Emulsion and Chorhexidine digluconate at same time point and 515 
concentration. 516 
517 
Fig.  12. The percentage kill of ATCC CRL-2692- human oesophageal tissue monolayer cells 518 
after 5, 30 and 60 minutes exposure to varying concentrations of ML:8 emulsion and 519 
Chlorhexidine digluconate (CHX).  Results are obtained via the use of an alamarBlue® assay (10 520 
hour development time).  Key: 521 
 522 
ns: no significant difference (P>0.05), *: P<0.05, **: P<0.01, ***: P<0.001, significant difference 523 
between cytotoxicity of ML:8 Emulsion and Chorhexidine digluconate at same time point and 524 
concentration. 525 
 526 
 527 
 528 
